COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF МOXIFLOXACIN AND LEVOFLOXACIN THERAPY IN THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA.
Abstract
Community-acquired pneumonia is an urgent problem that requires effective treatment. For effective treatment of pneumonia, it is necessary to choose the right fluoroquinolone, taking into account the sensitivity of the pathogen and the pharmacokinetic characteristics of the drug. In this case, it is necessary to take into account the pronounced side effects and limitations of the use of these drugs. An important step is to determine the dosage and duration of treatment. The effectiveness and safety of treatment of pneumonia with fluoroquinolones is manifested in clinical and laboratory parameters. This article reviews a comparative study of moxifloxacin with levofloxacin in the treatment of community-acquired pneumonia, and compares the effectiveness and safety of these drugs.
References
Fluoroquinolones in the management of communityacquired pneumonia in primary care Expert Rev. Anti Infect. Ther. 8(11), 1259–1271 (2010)
Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia Author links open overlay panelJames Bradley MD a, Nadine Sbaih MD b, Thomas R. Chandler MPH c, Stephen Furmanek MS, MPH c, Julio A. Ramirez MD c, Rodrigo Cavallazzi MD
Sex and gender differences in community-acquired pneumonia Bernadette Corica, Francesco Tartaglia, Tania D’Amico, Giulio Francesco Romiti & Roberto Cangemi
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and Safety of Moxifloxacin Therapy versus That of Levofloxacin Therapy Antonio Anzueto, Michael S. Niederman, James Pearle, Marcos I. Restrepo, Albrecht Heyder, Shurjeel H. Choudhri, Community-Acquired Pneumonia Recovery in the Elderly Study Groupat
Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin Jamal Wadi Al Ramahi1,2 , Mustafa Ramadan 2 , Waad Jaber2 , Lamya Abushanab3 , Mohammad Mughrabi3 , Noor Alshamayleh3 , Ahmad Mulhem3 , Dania Momani1 , Mohammad Obaidat3 , Ghayda Haddad1 , Basma Khalil2 , Anas Zahran4 , Esraa Odat4 , Nadeen Kufoof4 , Haneen Arabiat4 , Amr Diab2 ,
Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation Xiwen Du, MPH1; Yi Han, PhD2; Yifei Jian, MS2; Liping Chen, MS2; and Jianwei Xuan, PhD2 1Shanghai Centennial Scientific Co Ltd, Shanghai, China; and 2School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
Fluoroquinolones in the management of communityacquired pneumonia T. E. Albertson,1,2 N. C. Dean,3,4 A. A. El Solh,5 M. H. Gotfried,6 C. Kaplan,7 M. S. Niederman8,9
